bluebird bio (BLUE) Confirms FDA Approval of ZYNTEGLO Gene Therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
bluebird bio (BLUE) Falls to Low, Down 18%
August 18, 2022 10:38 AM EDTbluebird bio (NASDAQ: BLUE) Falls to Low, Down 18%
... MoreUPDATE: bluebird bio's (BLUE) Zynteglo Gets FDA Approval - List Price In-Line Says Analyst
August 17, 2022 4:22 PM EDT(Updated - August 17, 2022 4:23 PM EDT)
bluebird bio's (NASDAQ: BLUE) cell-based gene therapy, Zynteglo, has been approved for the treatment of adult and pediatric patients with beta-thalassemia by the U.S. Food and Drug Administration, it was announced Wednesday.
Beta-thalassemia is a type of inherited blood disorder that causes a reduction of normal hemoglobin and red blood cells in the blood. Zynteglo is the first cell-based gene therapy to treat the blood disorder.
Zynteglo is a one-time gene therapy product administered as a single dose. Its safety and effectiveness were established in... More
bluebird bio (BLUE) Resumes Trading, Up 20%
August 17, 2022 2:30 PM EDTbluebird bio (NASDAQ: BLUE) Resumes Trading, Up 20%
... Morebluebird bio (BLUE) to Resume Trading at 2:30 p.m.
August 17, 2022 2:10 PM EDTbluebird bio (NASDAQ: BLUE) to Resume Trading at 2:30 p.m.
... Morebluebird bio (BLUE) to Charge $2.8M for Fda-Cleared Blood Disorder Therapy - Bloomberg
August 17, 2022 1:54 PM EDTbluebird bio (NASDAQ: BLUE) to Charge $2.8M for Fda-Cleared Blood Disorder Therapy - Bloomberg
... MoreFDA Approves bluebird bio's (BLUE) Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions
August 17, 2022 1:40 PM EDTToday, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
"Today's approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing red blood cell transfusions," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "Given the potential health complications associated with this serious disease, this action highlights the FDA's continued commitment to supporting development of innovative therapies for patients who... More
bluebird bio (BLUE) Halted, News Pending
August 17, 2022 12:41 PM EDTbluebird bio (NASDAQ: BLUE) Halted, News Pending
... More